Novartis News

Company ( PRGO ) recently received some good news when the U.S. Food and Drug Administration (FDA) cleared its generic version of Novartis ' ( NVS ) heart burn drug Prevacid. Approval was granted to treat patients suffering from frequent heartburn (two or

of our product pipeline and related technologies. GenVec's novel treatment for hearing loss and balance disorders, partnered with Novartis AG, is on its path towards the commencement of human clinical trials and we will work together to see that our human

the P/E ratio of the stock experienced a substantial increase and stood at 18.2x against 13x in FY10. Johnson & Johnson’s peer Novartis has a trailing PE ratio of 14.7 and yields 4.7%. The stock is expected to have a single digit PE ratio by the end of 2013.

year, respectively. Novartis has a co-promotion agreement with Eisai and Co. Ltd (ESALY) in Japan. Though we are pleased with Novartis’ wide range of products and its efforts to diversify further, we prefer to remain on the sidelines in the long term. We remain

discrimination against pregnant workers has gained notice within the pharmaceutical industry. Two years ago, for instance, Novartis agreed to pay $152.5 million to settle a class action discrimination lawsuit brought by female sales reps after a federal jury

assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking

(licensed by the FDA and sold by Novartis as "Transderm Scop" sea-sickness patches) is the ? I learn something new every day. Scopolamine is not new at all. It was the drug of choice for labor in the '50s and '60s, into the early '70s. Mom had it when she

2012 at McCormick Place in Chicago, Illinois. Array invented selumetinib and MEK162 and subsequently licensed them to AstraZeneca and Novartis, respectively. Three oral presentations at ASCO: Selumetinib Title: Phase II double-blind, randomized study of selumetinib

me in automatically next time Novartis' NVA237 still GLOWing one year on Today Pial Ganguli Please Login to read the full article. This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street,

efficacy to open-label tiotropium or Spiriva from Pfizer and Boehringer Ingelheim, in patients with moderate-to-severe COPD. Novartis has carried out late-stage trials for NVA237, as it looks to tap into the lucrative market for respiratory drugs at a time